# The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China

> **NCT04228393** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Wei Zhao** · enrollment: 82 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia, Pediatric

## Interventions

- **DRUG:** 6-mercaptopurine
- **PROCEDURE:** Standard treatment
- **PROCEDURE:** Individualized treatment

## Key facts

- **NCT ID:** NCT04228393
- **Lead sponsor:** Wei Zhao
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2020-01-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04228393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04228393, "The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04228393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*